Tubulis
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $489M
Overview
Develops superior antibody-drug conjugates with enhanced stability and potency to treat various cancers more effectively.
Oncology
Technology Platform
A proprietary platform for generating homogeneous and stable antibody-drug conjugates using novel linker and payload technologies.
Funding History
2Total raised:$489M
Venture$361M
Series B$128M
Opportunities
Potential to unlock new targets and cancer types with its more stable and potent ADC constructs.
Risk Factors
Preclinical promise may not translate to clinical efficacy, and the complex manufacturing of ADCs presents scalability challenges.
Competitive Landscape
Operates in a competitive ADC sector dominated by large pharma, but its focus on technological innovation in linker/payload design is a key differentiator.